Industrial Farmacéutica Cantabria, S.A.
Abrir el Menú Móvil

OUR HISTORY

1989

The drug Difur
marked our first
steps in the field of
dermatology.

1995

We discovered
and patented oral
photoprotection in
collaboration with
Harvard University.

1997

We signed an agreement for the
distribution of Neostrata in Spain,
working with them to develop
additional products specifically suited
to individual markets.

1994

The Matji family purchased 100% of
the shares of Industrial Farmaceutica
Cantabria, now Cantabria Labs, from the
company Andrómaco-Grünenthal.

1996

We created Isolagen Europe
thus becoming a pioneer in cell
therapy in the field of dermatology.
The company produces high-tech
autologous cell cultures.

2001

The International division was
created to meet the growing
demand for our products and
market them worldwide through
a global network of distribution partners.

2002

We divested our generic products
business(UR), freeing up more resources
to focus on the field of dermatology.

2006

• We purchased the Brazilian dermatology company
Melora do Brasil S.A., which was divested a decade later.
• We divested a number of drug businesses.
We acquired new rights and patents specifically
related to the field of dermatology such as
RetinSphere® and RTF1.

2003

Difa Cooper, an Italian dermatology company,
entered the family with the goal of
expanding its product portfolio with
ingredients, technologies, and innovative,
cutting-edge products.

2007

• We acquired 95% of the shares of the Belgian
company HDP, specialized in the
distribution of dermocosmetic products.
The action consolidated our presence in the
Benelux market, advancing its positioning in Europe.
• We gambled on the market of functional ingredients
and foods for human and veterinary consumption
with the creation of Gourmetceuticals LLC,
penetrating the US market with original
ingredients for the development of functional
gourmet products.

2008

• The activities in the
North American market
accelerated through a
commercial agreement
with Ferndale Labs, thus
consolidating Heliocare Oral.
• One of the star ingredients
in the American market
is introduced: Fernblock® (PLE).

2011

• We purchased from GSK
the rights to a line of leading
corticosteroids in the Spanish
market: Clovate®, Emovate®,
and Betnovate®, expanding
the portfolio of specific
dermatological products for
inflammatory skin diseases.
• We purchased the rights
to new technologies applied
to alopecia, acne,
hyperpigmentation, and photo-aging.

2013

With Nutrición Médica in the
family, we introduced ourselves
to specialization in clinical
nutrition products: oncology,
radiotherapy, and geriatrics.
In addition, we diversified
product portfolio and solutions,
optimizing the use of Cantabria
Labs ingredients in food for
special medical use.

2009

• We launched the patent for
a new molecule developed
to contribute to the
regeneration of stem cells.
• We consolidate ourselves in
the Iberian Peninsula with
the creation of
Cantabria Labs Portugal.

2012

The RIO project of
Operational Excellence
is launched, based on
the study and improvement
of all work processes within
the company: commercial,
administrative, technological,
and production.

2014

• Thanks to our growth potential,
we were selected to participate in
the Cre100do project, an initiative
promoted by the Bankinter Innovation
Foundation, ICEX and Círculo de
Empresarios.
• After eight years out of our
portfolio, Inmunoferón® returned
to strengthen our healthcare
product offer.
• We invested in Prokrea BCN,
a biotech company specialized
in the development of patented
pharmaceutical products for
the treatment of infertility in couples.

2015

• ZO Skin Health arrived in
Spain through Cantabria Labs.
The concept of medical cosmetics
took root in the Spanish market.
• The branch in Morocco was created
and the development and international
expansion plan was expanded
to reinforce our
presence in the African market.

2016

• We obtained the approval for production
of NSF nutraceutical supplements.
• We became part of the shareholders of Histocell,
a company specializing in regenerative medicine and cell therapy.
• We purchased 60% of Avance Cosmetics and opened a new
commercial retail channel: telemarketing media and direct response.
• We expanded and diversified medical specialties to reach
pediatrics with Inmunoferon and otorhinolaryngology.
• We signed a 20-year licensing agreement with Krymi Laboratori.
• start of the building of our new sustainable
production center in La Concha (Cantabria).

2017

• Cantabria Labs Mexico was
born, with the goal of expanding
our products and solutions in
the American market.
• As a result of an ambitious
international expansion plan,
Cantabria Labs China was
created in a strategic and key market
for growth in healthcare.
• We obtained new scientific endorsement
for IFC®-CAF through a study led
and published by Dr. Zoe Diana Draelos.

• We launched our new patented Edafence®
technology, based on the Deschampsia
antarctic plant.
• We signed an agreement with the
Massachusetts Institute of
Technology (MIT) through which
we will sponsor and promote
MIT's biomedical innovation
programs and activities.
• Cantabria Labs Difa Cooper was
recognized for its high
quality as a place to work
with the 'Great Place to Work' award.

• Our Endocare-C Proteoglycan Oil-Free
ampoules received the "T de Telva"
award for most innovative cosmetic.
• We received an innovation award
in the "VI Premios a tu Salud" of
La Razón for the scientific endorsement
of our products, the support of
professionals, and our
reference work in R+D+i.
• We adopted a new corporate identity
aligned with our values, our
natural evolution: Cantabria Labs.

1989

The drug Difur marked our first steps in the field of dermatology.

1994

The Matji family purchased 100% of the shares of Industrial Farmaceutica Cantabria, now Cantabria Labs, from the company Andrómaco-Grünenthal.

1995

We discovered and patented oral photoprotection in collaboration with Harvard University.

1996

We created Isolagen Europe thus becoming a pioneer in cell therapy in the field of dermatology.
The company produces high-tech autologous cell cultures.

1997

We signed an agreement for the distribution of Neostrata in Spain, working with them to develop additional products specifically suited to individual markets.

2001

The International division was created to meet the growing demand for our products and market them worldwide through a global network of distribution partners.

2002

We divested our generic products business(UR), freeing up more resources to focus on the field of dermatology.

2003

Difa Cooper, an Italian dermatology company, entered the family with the goal of expanding its product portfolio with ingredients, technologies, and innovative, cutting-edge products.

2006

• We purchased the Brazilian dermatology company Melora do Brasil S.A., which was divested a decade later.
• We divested a number of drug businesses. We acquired new rights and patents specifically RetinSphere® and RTF1.

2007

• We acquired 95% of the shares of the Belgian company HDP, specialized in the distribution of dermocosmetic products.
The action consolidated our presence in the Benelux market, advancing its positioning in Europe.
• We gambled on the market of functional ingredients and foods for human and veterinary consumption with the creation of Gourmetceuticals LLC,
penetrating the US market with originalingredients for the development of functional gourmet products.

2008

• The activities in the North American market accelerated through a commercial agreement with Ferndale Labs, thus consolidating Heliocare Oral.
• One of the star ingredients in the American market is introduced: Fernblock® (PLE).

2009

• We launched the patent for a new molecule developed to contribute to the regeneration of stem cells.
• We consolidate ourselves in the Iberian Peninsula with the creation of Cantabria Labs Portugal.

2011

• We purchased from GSK the rights to a line of leading corticosteroids in the Spanish market: Clovate®, Emovate®, and Betnovate®, expanding the portfolio of specific dermatological products for inflammatory skin diseases.
• We purchased the rights to new technologies applied to alopecia, acne, hyperpigmentation, and photo-aging.

2012

The RIO project of Operational Excellence is launched, based on the study and improvement of all work processes within the company: commercial, administrative, technological, and production.

2013

With Nutrición Médica in the family, we introduced ourselves to specialization in clinical nutrition products: oncology, radiotherapy, and geriatrics.
In addition, we diversified product portfolio and solutions, optimizing the use of Cantabria Labs ingredients in food for special medical use.

2014

• Thanks to our growth potential, we were selected to participate in the Cre100do project, an initiative promoted by the Bankinter Innovation Foundation, ICEX and Círculo de Empresarios.
• After eight years out of our portfolio, Inmunoferón® returned to strengthen our healthcare product offer.
• We invested in Prokrea BCN, a biotech company specialized in the development of patented pharmaceutical products for the treatment of infertility in couples.

2015

• ZO Skin Health arrived in Spain through Cantabria Labs.
The concept of medical cosmetics took root in the Spanish market.
• The branch in Morocco was created and the development and international expansion plan was expanded to reinforce our presence in the African market.

2016

• We obtained the approval for production of NSF nutraceutical supplements.
• We became part of the shareholders of Histocell, a company specializing in regenerative medicine and cell therapy.
• We purchased 60% of Avance Cosmetics and opened a new commercial retail channel: telemarketing media and direct response.
• We expanded and diversified medical specialties to reach pediatrics with Inmunoferon and otorhinolaryngology.
• We signed a 20-year licensing agreement with Krymi Laboratori.
• start of the building of our new sustainable
production center in La Concha (Cantabria).

2017

• Cantabria Labs Mexico was born, with the goal of expanding our products and solutions in the American market.
• As a result of an ambitious international expansion plan, Cantabria Labs China was created in a strategic and key market for growth in healthcare.
• We obtained new scientific endorsement for IFC®-CAF through a study led and published by Dr. Zoe Diana Draelos.

• We launched our new patented Edafence® technology, based on the Deschampsia antarctic plant.
• We signed an agreement with the Massachusetts Institute of Technology (MIT) through which we will sponsor and promote MIT's biomedical innovation programs and activities.
• Cantabria Labs Difa Cooper was recognized for its high quality as a place to work with the 'Great Place to Work' award.

• Our Endocare-C Proteoglycan Oil-Free ampoules received the "T de Telva" award for most innovative cosmetic.
• We received an innovation award in the "VI Premios a tu Salud" of La Razón for the scientific endorsement of our products, the support of professionals, and our reference work in R+D+i.
• We adopted a new corporate identity aligned with our values, our natural evolution: Cantabria Labs.

We use own and third party cookies to improve our services and show you contents related to your browsing habits. If you go on navigating, we will consider you accept its use. Click here to change the settings or get more information.ACCEPT